LYMA sales soar following US expansion
British MedTech company LYMA has reported revenues of £36 million for the year ending 31 December 2025, with growth driven by its expansion into the US.
Following established success in the UK, LYMA entered the US market in April 2025 with the launch of its FDA-cleared LYMA Laser PRO.
Ahead of the April release, more than 16,000 customers joined a waitlist, representing demand of over $100 million for the device, which retails at close to $6,000.
The US has since become the company’s largest market, accounting for over 70% of global sales, with direct-to-consumer revenue growing by 130% in the first six months after launch.
Lucy Goff, Founder and CEO of LYMA, said: "2025 was a transformative year for LYMA as we solidified our position in the US market and demonstrated the global appetite for truly innovative regenerative technology.
"Our success reflects our unwavering commitment to delivering clinically-proven results through cutting-edge science, and we’re seeing that resonate particularly strongly with American consumers who demand both efficacy and luxury."
LYMA plans to continue expanding in both the UK and UK throughout 2026, while developing its presence in additional markets including Australia and the UAE.
The company also confirmed that further product innovation is in development, with new launches planned for later this year.
